Adendra Therapeutics develops dendritic cell‑focused immunotherapies for solid tumors and autoimmune diseases. By engineering vectors that deliver tumor‑specific or autoantigen peptides together with proprietary adjuvant blends, the platform enhances antigen presentation and steers immune responses for either tumor eradication or immune tolerance. The modular, GMP‑compatible system enables rapid creation of personalized vaccine candidates and combination‑ready formats for pharmaceutical partners.

Aethon Therapeutics uses its HapImmune™ platform to engineer antibodies that create synthetic neoantigens on drug‑resistant cancer cells after exposure to targeted therapies, such as KRAS‑G12C inhibitors. These hapten‑peptide constructs flag the resistant cells for immune clearance, enabling selective antibody‑mediated killing while sparing normal tissue. The modular system is designed for partnership with pharmaceutical and biotech companies to enhance the durability of targeted oncology treatments.

Akero Therapeutics is developing Efruxifermin (EFX), a therapeutic agent aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) by restoring metabolic balance in patients. The company conducts clinical trials to evaluate the efficacy of EFX in reversing the progression of this serious liver disease.

Ant provides a voice-activated payment system that transforms smartphones into point-of-sale terminals, enabling micro-enterprises in Africa to accept secure, instant payments without the need for traditional POS hardware. This technology addresses the challenges of cash dependency and financial invisibility faced by millions of small business owners, facilitating their integration into the formal economy.

Apertor develops novel molecular glues using a synthetic biology platform that leverages non-model organisms and a structure-guided computational design pipeline for therapeutic applications in oncology. The company focuses on creating first-in-class treatments for age-related diseases, addressing significant pharmacological challenges in cancer therapy.

Ascidian Therapeutics develops a proprietary RNA exon editing platform that enables precise post-transcriptional modifications to replace multiple contiguous exons, addressing genetic mutations that vary among patients. This technology allows for the production of full-length, functional proteins at appropriate levels and in the correct cells, providing a safer alternative to traditional gene editing methods.

Aulos Bioscience is developing imneskibart (AU‑007), an AI‑designed human monoclonal antibody that blocks interleukin‑2 binding to the CD25 subunit on regulatory T cells while preserving its activity on CD8⁺ effector cells. By shifting IL‑2 signaling toward immune activation and away from suppression, the therapy aims to deliver safer, more potent immunotherapy for patients with unresectable or metastatic solid tumors, with subcutaneous dosing and reduced vascular leak toxicity.

Chinook Therapeutics develops targeted therapeutics that focus on addressing significant disease burdens, particularly in kidney diseases. By utilizing advanced biological research and technology, the company aims to enhance patient outcomes and extend life expectancy.

Deep Apple Therapeutics uses a deep learning‑driven platform that combines cryo‑EM structural data, AI‑based pocket extraction, molecular dynamics, and ultra‑high‑throughput virtual screening of massive internal libraries to identify novel small‑molecule candidates. By modeling protein flexibility and rapidly evaluating billions of virtual compounds, the engine accelerates discovery and optimization of therapeutics for inflammatory, immune, metabolic, and endocrine targets, offering pharma and biotech partners a faster path to potent drug candidates.

DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.

Galvanize is a biomedical platform company that develops proprietary pulsed electric field (PEF) technologies to selectively eliminate disease‑associated cells without thermal injury. Its integrated catheter and device systems enable minimally invasive, precision treatments for cardiac, pulmonary, oncologic, and vascular conditions, supported by a full clinical development pipeline and partnership model for hospitals and interventional physicians.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Initial Therapeutics develops small-molecule medicines that inhibit the synthesis of pathogenic proteins associated with diseases caused by protein misfolding and aggregation. This approach targets conditions linked to dysfunctional protein production, providing a potential therapeutic pathway for affected patients.

The startup operates a clinical-stage biotech company that utilizes a platform for T-cell activation through co-stimulation of the T-cell receptor and a secondary signal, specifically targeting tumor-infiltrating lymphocytes. This approach aims to enhance the efficacy of cancer treatments by consistently activating T-cell subsets that are crucial for combating tumors.

Marlin provides a blockchain-agnostic relay network that enables verifiable offchain execution of computations using Trusted Execution Environments (TEEs) and zero-knowledge proofs. This technology allows developers to build scalable decentralized applications while significantly reducing onchain costs and protecting intellectual property.

Nereid Therapeutics utilizes proprietary technologies to measure and visualize liquid-liquid phase separation (LLPS) in mammalian cells, enabling the discovery of small molecules that can modulate protein interactions involved in diseases like cancer and inflammatory disorders. By providing precise insights into biomolecular condensates, the company addresses the challenge of developing effective treatments for intractable diseases that have limited therapeutic options.

Nine Square Therapeutics focuses on accelerating the development of novel therapeutics for neurodegenerative diseases. The company pursues challenging and previously undruggable biological targets to create better treatment options. Their approach is driven by innovation to alter the trajectory of serious neurological conditions.

Develops antiviral therapeutics using a stapled lipopeptide platform that inhibits virus-cell fusion, preventing viral entry and accelerating clearance without relying on immune activation. This approach targets enveloped viruses, including SARS-CoV-2, RSV, and influenza, offering stable, room-temperature formulations for rapid self-administration via nasal spray, inhaler, or injection.

Replicate Bioscience develops self-replicating RNA (srRNA) immunotherapies to prevent and reverse drug resistance in cancer treatments. Their platform enhances protein expression within cells, enabling the detection and elimination of cancerous cells while improving the effectiveness of immuno-oncology therapies.

Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

The startup offers a platform that enables businesses to generate revenue without any upfront investment by providing a full customer experience service and 360-degree protection for their financial solutions. It addresses the challenge of financial accessibility and inflation risk, allowing users to earn guaranteed cash while minimizing their financial exposure.

Tend is a technology-driven dental company that utilizes a proprietary app for easy appointment booking, treatment tracking, and transparent pricing, enhancing patient engagement and convenience. The company provides a full range of dental services, including exams, orthodontics, and emergency care, in a judgment-free environment, addressing the common issues of accessibility and anxiety in dental visits.

Tern provides a low-code platform for brands to quickly launch customizable banking products, including virtual and physical prepaid cards, while ensuring compliance through robust back-office tools. This solution addresses the need for efficient onboarding and fund management in a secure environment, enabling businesses to streamline financial operations and enhance cash flow.